Genaera Corporation Announces Second Quarter Financi... ( PLYMOUTH MEETING Pa. Aug. 11 /- G...)

Genaera Corporation Announces Second Quarter Financial Results

Date:8/11/2008

PLYMOUTH MEETING, Pa., Aug. 11 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced its financial results for the three- and six-month periods ended June 30, 2008. The net loss for the three-month period ended June 30, 2008 was $4.8 million, or $(0.27) per share basic and diluted, as compared to a net loss of $2.0 million, or $(0.11) per share basic and diluted, for the three-month period ended June 30, 2007. The net loss for the six-month period ended June 30, 2008 was $9.0 million, or $(0.52) per share basic and diluted, as compared to a net loss of $6.2 million, or $(0.35) per share basic and diluted, for the six-month period ended June 30, 2007.

Genaera's research and development expenses for the three- and six-month periods ended June 30, 2008 were $3.5 million and $7.4 million, respectively, compared to $3.1 million and $6.6 million, respectively, for the same periods in 2007. The increase was primarily due to increases in research and clinical costs related to the trodusquemine (MSI-1436) program for the treatment of obesity and type 2 diabetes and increases in stock-based compensation expense. These increases were partially offset by decreases in manufacturing and personnel costs associated with the MSI-1436 program and decreases in clinical, manufacturing, research and personnel expenses as a result of the termination of the squalamine program for the treatment of wet age-related macular degeneration and the LOMUCIN(TM) program for the treatment of cystic fibrosis in 2007.

Genaera's general and administrative expenses for the three- and six-month periods ended June 30, 2008 were $1.4 million and $3.6 million, respectively, compared to $1.6 million and $3.1 million, respectively, for the same
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Genaera Elects New Board Member and Announces Executive Appointments
2. Genaera to Present at Biotech 2007 and BIO InvestorForum
3. Genaera Corporation Announces Third Quarter Financial Results
4. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
5. Genaera Corporation Announces 2007 Financial Results
6. Genaera Corporation Announces First Quarter Financial Results
7. Genaera Corporation to Present at BIO Business Forum
8. Genaera Corporation Elects Paul K. Wotton to Board of Directors
9. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II

Post Your Comments:

(Date:12/15/2009)... of three Department of Energy (DOE) bio-energy research centers, ... its valuable intellectual property. , ... ... -- Surety, LLC , the leading provider of ... the Joint BioEnergy Institute (JBEI), one of three Department ...

(Date:12/15/2009)... 15 Aethlon Medical, Inc. (OTC Bulletin ... Schorey and Dr. Wayne Comper have ... Inc. (ESI). Both Dr. Schorey and Dr. Comper ... a wholly owned subsidiary of Aethlon Medical, was ... Hemopurifier®, a medical device being advanced as an ...

(Date:12/15/2009)... -- The International Society for Medical Publication Professionals ... continuing to accept abstracts for its 6th Annual ... April 19-21, 2010. This marks the first time ... the organization to submit an abstract to this ... AM EST, January 15, 2010. For submission details, ...

(Date:12/15/2009)... December 15 , ... to Evaluate the Ability of,Cardiopoietic Cells to Restore ... BioSciences, a leading Belgian biotechnology company specialising,in cell-based ... that it has completed, two months ahead of ... Phase II/III trial of C-Cure, a,unique stem cell ...

Breaking Biology Technology:Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 2 Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 3 Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 4 Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 5 Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 2 Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 3 Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 4 Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 5 The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 2 The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 3 Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 2 Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 3

[0] Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property [0] Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board [0] The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting [0] Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure

... Ceres, Inc. announced today,that it has begun booking ... label. The highly anticipated launch marks the first seed,sales ... biofuels and biopower. The company simultaneously launched a Blade ... The company reported that the first Blade ...

... Cornerstone Therapeutics Inc. (Nasdaq: CRTX ), ... commercializing prescription medications for respiratory disorders, today provided ... activities following the closing of the business combination ... Inc. on October 31, 2008, and the renaming ...

... TORONTO, Dec. 11 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: ... tests for the early detection of diseases and ... entered into a agreement allowing Centocor Research & ... osteoarthritis genomic biomarker program. Additional terms of the ...

Other Biology Technology:First Seed Sales of Dedicated Energy Crops Begin 2 First Seed Sales of Dedicated Energy Crops Begin 3 Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance 2 Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance 3 Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance 4 Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance 5 GeneNews provides Centocor access to its osteoarthritis program 2

First Seed Sales of Dedicated Energy Crops Begin Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance GeneNews provides Centocor access to its osteoarthritis program

(Date:12/15/2009)... a team of Spanish and American researchers found the fossil ... Huelva. Now they have published, for the first time, the ... the death of the young cetacean, possibly a baleen whale ... discovery of the partial fossil remains of a whale from ... Sands sedimentary formation, but it is the first time that ...

(Date:12/15/2009)... model organism, but there are currently few resources ... blood-forming tissues in this species. A newly ... from Cold Spring Harbor Laboratory Press fills this ... protocols for the preparation, enumeration, and microscopic examination ... tissues in the mouse. The laboratory manual ...

(Date:12/14/2009)... AlaskaScientists have identified a novel antifreeze molecule in a ... 100 degrees Fahrenheit. Unlike all previously described biological antifreezes ... little or no protein. It is composed of a ... new places within the cells of organisms. , ... this molecule is a whole new kind of antifreeze ...

[0] Story of 4.5 million-year-old whale unveiled in Huelva [0] New source of classical techniques for blood-based studies in the laboratory mouse [0] Scientists isolate new antifreeze molecule in Alaska beetle

... a few nights without enough sleep and you're more likely ... how sleep is related to the immune system. Now, researchers ... fruit flies can point to the answers. , What they ... may be a two-way street: sick flies can't sleep, and ...

... Researchers observing wild chimpanzees in Uganda have discovered repeated ... infanticide. The findings, reported by Simon Townsend, Katie Slocombe ... and the Budongo Forest Project, Uganda, appear in the ... by Cell Press. , Infanticide is known to occur ...

... early or localized prostate cancer, taking too many multivitamins ... or fatal prostate cancers, according to a study in ... the National Cancer Institute . , Millions of Americans ... health benefits, even though there is limited scientific evidence ...

Other Biology News:Sleepless for science: Flies show link between sleep, immune system in Stanford study 2 Sleepless for science: Flies show link between sleep, immune system in Stanford study 3 Female-led infanticide in wild chimpanzees 2 Heavy multivitamin use may be linked to advanced prostate cancer 2

Sleepless for science: Flies show link between sleep, immune system in Stanford study Female-led infanticide in wild chimpanzees Heavy multivitamin use may be linked to advanced prostate cancer

...

Chicken Aortic Smooth Muscle Cells (CAOSMC) (>500,000 cells)...

Canine Chondrocytes (CnC) (500,000 cells)...

B-FABP (FL-132)...

Biology Products:

HEPA Filtered Single Chamber Water Jacketed Incubator, CO2/O2 IR, 115V, 50/60 Hz from Thermo Scientific CAOSMC (C354-05) from European Collection of Cell Cultures (ECACC)CnC (Cn402-05) from European Collection of Cell Cultures (ECACC)Rabbit Anti-B-FABP (FL-132) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.

Genaera Corporation Announces Second Quarter Financi...( PLYMOUTH MEETING Pa. Aug. 11 /- G...)